|
|
|
|
|
|
|
Zymeworks Inc (ZYME)
|
|
17.7 0.69 (4.06%)
|
05-21 16:02
|
|
Open:
|
17.27
|
Pre. Close:
|
17.01
|
|
High:
|
17.97
|
Low:
|
17.01
|
|
Volume:
|
83,297
|
Market Cap:
|
454M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
17.987 - 18.074
|
18.074 - 18.149
|
|
Low:
|
16.808 - 16.905
|
16.905 - 16.99
|
|
Close:
|
17.55 - 17.705
|
17.705 - 17.839
|
|
|
|
Technical analysis (as of: 2018-05-21 4:35:11 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a BUY today, upgraded from lower rating. This stock seems to be ready for a new bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, a new upward move is expected.
|
|
Target:
|
Six months: 21.02 One year: 24.56
|
|
Support:
|
Support1: 14.07 Support2: 11.64
|
|
Resistance:
|
Resistance1:
18.00 Resistance2: 21.02
|
|
Pivot:
|
15.56
|
|
Moving Averages:
|
MA(5): 15.93 MA(20): 15.29
MA(100): 11.80 MA(250): 9.73
|
|
MACD:
|
MACD(12,26):
0.81 Signal(12,26,9): 0.87 
|
|
%K %D:
|
%K(14,3): 59.35 %D(3): 61.36
|
|
RSI:
|
RSI(14): 59.80
|
|
52-Week:
|
High: 18
Low: 6.25 Change(%): 35.4
|
|
Average Vol(K):
|
3-Month: 4090
10-Days 8636
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.ZYME has closed below upper band by 11.8%. Bollinger Bands are 72.5% wider than normal. The large width of the bands suggest high volatility as compared to ZYME's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue.
|
|
|
Headline News
|
|
2018-05-15T06:55:49-04:00
Zymeworks expands I-O collaboration with Daiichi Sankyo
2018-05-14T17:00:00-04:00
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
2018-05-10T16:30:00-04:00
Zymeworks to Present at the UBS Global Healthcare Conference 2018
2018-05-04T05:00:00-04:00
Actinium Pharmaceuticals: Neglected Assets In Niche Oncology
2018-05-01T16:05:00-04:00
Zymeworks Reports 2018 First Quarter Financial Results
2018-04-30T16:05:00-04:00
Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018
2018-04-25T06:00:00-04:00
Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
2018-04-23T16:21:57-04:00
Zymeworks up 15% after hours on expanded Celgene partnership
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
